Close

Have A Question?


Connect with Camargo today.

Contact Us
Blog & Resources Webinars The 505(b)(2) Pathway: What is it? And What Does it Mean for Pre-IND and NDA Submission?

The 505(b)(2) Pathway: What is it? And What Does it Mean for Pre-IND and NDA Submission?

Date: May 29th, 2019

Presented by: Ken Phelps, president and co-founder, Camargo

Download

To bring a new drug to market, it can take more than a decade and cost upwards of $1 billion. What if there were a way to address global patient needs faster, less expensively, and with better outcomes?

In this webinar, Camargo co-founder Ken Phelps introduces the 505(b)(2) pathway and shares expert insights on: Identifying 505(b)(2) products Navigating regulatory milestones for 505(b)(2) products including IND and NDA preparation and submission Addressing frequently asked questions and common misconceptions surrounding 505(b)(2)


Get Our Diverse Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our Solutions or Contact Us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
2505 Meridian Parkway
Suite 150
Durham NC, 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights